Self-expanding stent insertion for XXXX : a 10-year follow-up.

@entity1 @entity322 @entity3832 @entity158 @entity850 @entity293
OBJECTIVE: To evaluate the safety and efficacy of the Urolume endourethral self-expandable metallic stent (American Medical Systems, MI, USA) in treating @entity3832 , based on a follow-up of> 10 years. @entity1 AND METHODS: Between November 1989 and June 1990, the Urolume stent was inserted into 15 @entity1 (aged 25-77 years) who had recurrent @entity3832 . The mean duration of stricture before stent insertion was 10.9 years. The @entity1 (all @entity1 ) were followed using a questionnaire and uroflowmetry, and if necessary, retrograde cysto-urethrography and/or urethroscopy and/or X-ray urodynamics. RESULTS: Two failures were caused by excessive tissue proliferation in the stent, which ended in stent removal or a suprapubic catheter. Another two stents were removed because of discomfort or @entity158 . Two @entity1 developed @entity850 in the stent after 7 and 9 years. In the final evaluation only two of the 15 @entity1 were satisfied with their stent. The mean maximum urinary flow rate at the last follow-up was 15 mL/s, and half the @entity1 noted 'stent' @entity322 . Lower @entity293 , urge and stress @entity322 , and discomfort with ejaculation, were all symptoms perceived at the last follow-up. CONCLUSION: The long-term results of the Urolume stent in this study weaken the optimistic early results. Only two of the 15 @entity1 were satisfied with their stent.
